RxDoctor Payments DataLook up a doctor →

Matthew Block, MD

Medical Oncology · Rochester, MNNPI 1356359111

Payments from drug & device makers

$8,072,970in general payments, 2019–2025

Across 71 payments — averaging $113,704 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$4.4M
  • Genentech, Inc.$2M
  • E.r. Squibb & Sons, L.L.C.$777K
  • Pharmacyclics LLC, An Abbvie Company$767K
  • Alkermes, Inc.$97K
  • Regeneron$55K
  • plus $2K from 1 others

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck22$4,355,488
Genentech, Inc.9$2,019,045
E.r. Squibb & Sons, L.L.C.8$777,157
Pharmacyclics LLC, An Abbvie Company8$766,861
Alkermes, Inc.19$97,215
Regeneron4$55,160
Organon1$2,044

How this compares

$8,072,970 in reported general payments places this provider in the 95th percentile of 133 medical oncology providers in Minnesota.

See all medical oncology providers in Minnesota

Medicare billing

Part B allowed, 2024
$2,822,706
Medicare patients
486
Services billed
89,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →